{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:58:59Z","timestamp":1785347939551,"version":"3.55.0"},"reference-count":31,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Objective: Voltage-gated potassium channel genes are among the most frequently implicated in epilepsy and antiseizure medication (ASM) response. In this pilot study, we aimed to identify rare and common variants by sequencing voltage-gated potassium channel (Kv) genes in epilepsy patients using ASM, and to reveal the potential drug responses of these variants. Methods: To investigate the role of genetic variants in Kv genes (KCNQ1, KCNQ2, KCNQ3, KCNA1, KCNA2, and KCNV2) in response to ASMs among 31 epilepsy patients, we used targeted next-generation sequencing (tNGS). Patients were classified as responders or persistent based on seizure control status. Selected variants in the genes were annotated, filtered, and analyzed for association with ASM response. Results: We identified 181 variants in the 6 channel genes, including missense, synonymous, intronic, UTR, and stop-gained variants. Six variants of uncertain significance (VUSs) were observed, including KCNA2c.*1314C&gt;T, KCNQ1c.*976G&gt;A, KCNQ2 (c.2613G&gt;T p.Arg871Ser and c.1148+62T&gt;G), and KCNQ3 (c.*6282A&gt;G and c.*2860T&gt;C). Two novel variants were identified in our study group, KCNA2:c.*1314C&gt;T and KCNQ3:c.*2860T&gt;C. Both were located in the 3\u2032 UTR region and classified as VUSs according to ACMG guidelines. In the KCNV2 gene, the CG haplotype comprising rs7029012 and rs10967705 was observed more frequently in patients with drug-persistent epilepsy than in those with drug-responsive epilepsy (18.5% vs. 0.8%; \u03c72 = 6.756, p = 0.009, BH-FDR q = 0.036), suggesting a potential association with pharmacoresistant epilepsy. Conclusions: Our haplotype analysis suggests the potential pharmacogenetic contribution of the KCNV2 gene to ASM response; however, these exploratory findings require validation in larger independent cohorts and functional studies.<\/jats:p>","DOI":"10.3390\/ph19081193","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:01:46Z","timestamp":1785344506000},"page":"1193","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted Sequencing and Haplotype Analysis of Voltage-Gated Potassium Channel Genes Reveal a Potential Association of KCNV2 Haplotypes with Antiseizure Medication Response in Turkish Patients with Epilepsy"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1056-960X","authenticated-orcid":false,"given":"Kubra Cigdem","family":"Pekkoc-Uyanik","sequence":"first","affiliation":[{"name":"Department of Medical Biology, Faculty of Medicine, Hali\u00e7 University, 34060 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Gizem","family":"Todurga-Seven","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmacology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, 34098 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhan Rasit","family":"Agay","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmacology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, 34098 Istanbul, Turkey"},{"name":"Sinan Sipahi Family Health Centre, Republic of Turkey Ministry of Health, 34295 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafize","family":"Uzun","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Faculty of Medicine, Istanbul Atlas University, 34408 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s12264-017-0191-5","article-title":"Mutations of N-Methyl-D-Aspartate Receptor Subunits in Epilepsy","volume":"34","author":"Xu","year":"2018","journal-title":"Neurosci. Bull."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/pr.117.014456","article-title":"Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies","volume":"70","author":"Oyrer","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"107966","DOI":"10.1016\/j.neuropharm.2020.107966","article-title":"Mechanisms of action of currently used antiseizure drugs","volume":"168","author":"Sills","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1146\/annurev-pharmtox-010617-052912","article-title":"KCNQ-Encoded Potassium Channels as Therapeutic Targets","volume":"58","author":"Barrese","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11910-008-0053-7","article-title":"New molecular targets for antiepileptic drugs: Alpha(2)delta, SV2A, and K(v)7\/KCNQ\/M potassium channels","volume":"8","author":"Rogawski","year":"2008","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"115413","DOI":"10.1016\/j.bcp.2023.115413","article-title":"Potassium channelopathies associated with epilepsy-related syndromes and directions for therapeutic intervention","volume":"208","author":"Gribkoff","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Faulkner, I.E., Pajak, R.Z., Harte, M.K., Glazier, J.D., and Hager, R. (2024). Voltage-gated potassium channels as a potential therapeutic target for the treatment of neurological and psychiatric disorders. Front. Cell. Neurosci., 18.","DOI":"10.3389\/fncel.2024.1449151"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zheng, Y., and Chen, J. (2024). Voltage-gated potassium channels and genetic epilepsy. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1466075"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/epi4.12934","article-title":"Potassium channel-related epilepsy: Pathogenesis and clinical features","volume":"9","author":"Zhao","year":"2024","journal-title":"Epilepsia Open"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"D\u00f6ring, J.H., Schr\u00f6ter, J., J\u00fcngling, J., Biskup, S., Klotz, K.A., Bast, T., Dietel, T., Korenke, G.C., Christoph, S., and Brennenstuhl, H. (2021). Refining Genotypes and Phenotypes in KCNA2-Related Neurological Disorders. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062824"},{"key":"ref_13","unstructured":"Adam, M.P., Bick, S., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993). KCNQ2-Related Disorders. GeneReviews\u00ae, University of Washington."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/ana.24080","article-title":"Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy","volume":"75","author":"Orhan","year":"2014","journal-title":"Ann. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"106580","DOI":"10.1016\/j.yebeh.2019.106580","article-title":"Safety of retigabine in adults with partial-onset seizures after long-term exposure: Focus on unexpected ophthalmological and dermatological events","volume":"102","author":"Brickel","year":"2020","journal-title":"Epilepsy Behav."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1021\/acs.chemrestox.8b00313","article-title":"An Investigation into Retigabine (Ezogabine) Associated Dyspigmentation in Rat Eyes by MALDI Imaging Mass Spectrometry","volume":"32","author":"Groseclose","year":"2019","journal-title":"Chem. Res. Toxicol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/jamaneurol.2023.3542","article-title":"Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial","volume":"80","author":"French","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1073\/pnas.1017539108","article-title":"Voltage-gated potassium channel KCNV2 (Kv8.2) contributes to epilepsy susceptibility","volume":"108","author":"Jorge","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","first-page":"E7","article-title":"Distinct epilepsy phenotypes and response to drugs in KCNA1 gain- and loss-of function variants","volume":"63","author":"Miceli","year":"2021","journal-title":"Epilepsia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/14728222.2021.1908263","article-title":"Potassium channels as prominent targets and tools for the treatment of epilepsy","volume":"25","author":"Nikitin","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1126\/science.1069424","article-title":"The structure of haplotype blocks in the human genome","volume":"296","author":"Gabriel","year":"2002","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Villa, C., and Combi, R. (2016). Potassium Channels and Human Epileptic Phenotypes: An Updated Overview. Front. Cell. Neurosci., 10.","DOI":"10.3389\/fncel.2016.00081"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e7321","DOI":"10.1097\/MD.0000000000007321","article-title":"Pharmacogenetic and case\u2013control study on potassium channel related gene variants and genetic generalized epilepsy","volume":"96","author":"Qu","year":"2017","journal-title":"Medicine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0028-3908(02)00237-X","article-title":"Potassium channels as anti-epileptic drug targets","volume":"43","author":"Wickenden","year":"2002","journal-title":"Neuropharmacology"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Al-Eitan, L.N., Al-Dalalah, I.M., Elshammari, A.K., Khreisat, W.H., and Almasri, A.Y. (2018). The Impact of Potassium Channel Gene Polymorphisms on Antiepileptic Drug Responsiveness in Arab Patients with Epilepsy. J. Pers. Med., 8.","DOI":"10.3390\/jpm8040037"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Lin, C.-H., Ho, C.-J., Chen, S.-Y., Lu, Y.-T., and Tsai, M.-H. (2024). Review of pharmacogenetics of antiseizure medications: Focusing on genetic variants of mechanistic targets. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1411487"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tang, F., Hartz, A.M.S., and Bauer, B. (2017). Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers. Front. Neurol., 8.","DOI":"10.3389\/fneur.2017.00301"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s11033-022-08142-1","article-title":"Next-generation sequencing of prolidase gene identifies novel and common variants associated with low prolidase in coronary artery ectasia","volume":"50","author":"Aslan","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"26511","DOI":"10.1038\/s41598-025-11843-9","article-title":"Next-generation sequencing of CCR5, CXCR4, and IFNAR1 variants in relation to HIV-1 disease progression and ART response","volume":"15","author":"Shahzadi","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1193\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:05:57Z","timestamp":1785344757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ph19081193"],"URL":"https:\/\/doi.org\/10.3390\/ph19081193","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]}}}